Skip to Content

Osimertinib for the Treatment of EGFR-Mutant NSCLC in the Adjuvant Setting

In this MEDtalk, associate professor Timothy F. Burns presents targetable treatment options for patients with early-stage non-small cell lung cancer (NSCLC), explicitly targeting the epidermal growth factor receptor (EGFR).

Timothy F. Burns

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top